Pegcetacoplan Markedly Reduces Proteinuria in C3 Glomerulopathy and Immune‑Complex MPGN: Results from the VALIANT Phase 3 Trial

Highlight

– Pegcetacoplan achieved a 67% geometric mean reduction in urinary protein-to-creatinine ratio at 26 weeks versus no meaningful change with placebo (relative reduction 68.1%; 95% CI, 57.3–76.2).
– Nearly half of treated patients met a composite endpoint of eGFR stabilization plus ≥50% proteinuria reduction (49% vs. 3% with placebo), and 60% had ≥50% proteinuria reduction (5% with placebo).
– Histologic activity scores did not differ in the biopsy subgroup at week 26; safety signals were comparable between groups with no confirmed serious infections from encapsulated bacteria reported.

Background and Clinical Context